top of page

2022 Rome Action Plan on Paediatric HIV & TB



All partners commit to: 


163. Address inequities by tackling the stigma and discrimination in communities, schools, and healthcare settings that prevent children living with HIV from accessing testing and treatment. 

164. Increase literacy about CD4 testing and viral load and promote a client-centred approach to support expansion of access to viral load for pregnant and breastfeeding women and children on treatment, including at the point-of-care. 

165. Review and assess emerging co-infections for immunocompromised infants and children, including those with advanced HIV disease, such as severe bacterial infections, fungal infections, and others for country consideration and implementation.

166. Engage affected communities for input and guidance on investment and programmatic priorities, provide support to in-country civil society organizations to engage in advocacy and demand creation for new tools, and ensure data is publicly available to support communities and civil society to monitor progress regarding uptake and implementation of essential diagnostic tools.




Stop TB Partnership’s Global Drug Facility commits to: 

435. Ensure priority formulations are appropriately communicated to suppliers, including in regular meetings with suppliers, GDF tenders, and at GDF’s supplier meetings. 

436. Ensure the TB Medicines Dashboard reflects current priority formulations and is updated regularly

437. Identify and implement mechanisms to de-risk suppliers who invest in development of child-friendly formulations. 

438. Continuously monitor and project demand for paediatric formulations to identify when the market would benefit from additional suppliers. 

439. Lead the external review of the TB section for each Global Fund’s Expert Review Panel Expression of Interest (GF ERP EOI) through TPMAT and suggest prioritization of formulations for expedited review.

440. Monitor the development pipeline and work with the Global Fund to expedite access to new formulations and medicines. 

441. Lead the TB Procurement and Market-Shaping Action Team (TPMAT) to coordinate global TB stakeholders and develop implementation roadmaps for new formulations. 

442. Work to build, stabilize and maintain access to small-volume products including child-friendly formulations for drug-resistant TB. 

443. Continue to use the Launchpad Approach to support the introduction and scale-up of paediatric formulations in programmes.

444. Provide technical assistance to support country TB programmes to quantify and forecast child-friendly formulations based on programmatic needs



bottom of page